Shionogi
Shionogi supply the best possible medicine to protect the health and wellbeing of the patients they serve.
- Healthcare
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
* | $375m | Grant | |
| Total Funding | 000k | ||
| EUR | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 13 % | 27 % | 2 % | 1 % | 13 % | 11 % | 3 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 38 % | 39 % | 39 % | 41 % | 40 % | 40 % | 40 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 34 % | 43 % | 37 % | 39 % | 35 % | 35 % | 35 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Shionogi & Company, Limited, a name synonymous with pharmaceutical innovation, traces its roots back to 1878 in Osaka, Japan. Founded by Gisaburo Shiono, the company began as a small apothecary, serving the local community with traditional Japanese and Chinese medicines. Over the years, Shionogi evolved, embracing Western pharmaceutical practices and expanding its reach.
A pivotal moment in Shionogi's history came in the 1950s when it shifted focus towards research and development, setting the stage for its future as a leader in the pharmaceutical industry. This strategic pivot led to the development of groundbreaking drugs, including the cholesterol-lowering medication Crestor, which became one of its flagship products.
In recent years, Shionogi has continued to innovate, particularly in the field of infectious diseases. The company made headlines when it was awarded $375 million by the U.S. Department of Health and Human Services to develop a long-acting therapeutic for COVID-19, highlighting its commitment to addressing global health challenges.
Today, Shionogi stands as a testament to over 140 years of dedication to improving health outcomes worldwide. Its journey from a local apothecary to a global pharmaceutical powerhouse underscores the impact of strategic foresight and relentless innovation in the ever-evolving landscape of healthcare.
Tech stack
